# EDGAR Filing Document

**Accession Number:** 0001716621
**File Stem:** 0001564590-23-001206
**Filing Date:** 2023-2
**Character Count:** 87875
**Document Hash:** 62818b920476572ffa13ca87e8a22a6b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001564590-23-001206.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0001564590-23-001206

**CONFORMED SUBMISSION TYPE**: S-3

**PUBLIC DOCUMENT COUNT**: 8

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230131

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ra Medical Systems, Inc.
- **CENTRAL INDEX KEY:** 0001716621
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 383661826
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269491
- **FILM NUMBER:** 23574411

**BUSINESS ADDRESS:**
- **STREET 1:** 5857 OWENS DRIVE, SUITE 300
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009
- **BUSINESS PHONE:** (760) 804-1648

**MAIL ADDRESS:**
- **STREET 1:** 5857 OWENS DRIVE, SUITE 300
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009

#### As filed with the Securities and Exchange Commission on January 31, 2023

#### Registration No. 333-

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM S-3

### REGISTRATION STATEMENT

#### UNDER

#### THE SECURITIES ACT OF 1933

------

## Ra Medical Systems, Inc.

#### (Exact name of registrant as specified in its charter)

------

---

| | |
|:---|:---|
| **Delaware** | **38-3661826** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

#### 1670 Highway 160 West, Suite 205

#### Fort Mill, SC 29708

#### 973-691-2000

#### (Address, including zip code, and telephone number, including area code of registrant's principal executive offices)

------

#### Jonathan Will McGuire

#### Chief Executive Officer

#### Ra Medical Systems, Inc.

#### 1670 Highway 160 West, Suite 205

#### Fort Mill, SC 29708

#### 973-691-2000

#### (Name, address, including zip code, and telephone number, including area code, of agent for service)

------

#### Copies to :
B. Joseph Alley, Jr., Esq.<br> **Arnall Golden Gregory LLP**<br> **Suite 2100**<br> **171 17<sup>th</sup> Street NW**<br> **Atlanta, Georgia 30363-1031**<br> (404) 873-8500<br>

------

#### Approximate date of commencement of proposed sale to the public: From time to time after the effective date of the registration statement.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

------

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
|  Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

**The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.**

------

**The information in this prospectus is not complete and may be changed. The Selling Stockholders may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting offers to buy these securities in any state where such offer or sale is not permitted.** 

#### SUBJECT TO COMPLETION, DATED JANUARY 31, 2023

#### PROSPECTUS
![](gozcc0r5i2o4000001.jpg)

### 331,608 Shares of Common Stock
This prospectus covers the offer and resale from time to time of up to 331,608 shares (the "**Shares**") of common stock, par value $0.0001 per share, of Ra Medical Systems, Inc., a Delaware corporation (the "**Company**"), by the Selling Stockholders identified in this prospectus, including their transferees, pledgees or donees or their respective successors. The Shares offered by the Selling Stockholders consist of 331,608 shares of common stock underlying the Company's Series E Common Stock Purchase Warrants (the "**Series E Warrants**") that were issued to the selling stockholders (the "**Selling Stockholders**") between January 9, 2023 and the date hereof, as part of the repricing of certain existing warrants (the "**Warrant Repricing**") pursuant to a January 9, 2023, warrant inducement offer letter ("**Inducement Letter**") entered into with Armistice Capital Master Fund Ltd. (the "**Master Fund**"), as previously reported on the registrant's Form 8-K filed January 13, 2023 (the "**Merger 8-K**"). The Series E Warrants will become exercisable upon certain stockholder approval as described further below, remain exercisable for five years thereafter, and have an exercise price of $4.00 per share, subject to adjustment.

Pursuant to the Inducement Letter, the Company has agreed to file a registration statement with the Securities and Exchange Commission ("Commission" or "SEC") that registers the resale of the Shares on behalf of the Selling Stockholders as soon as reasonably practicable and in no event later than 30 calendar days following the date of the Inducement Letter.

The Selling Stockholders identified in this prospectus may offer the shares of common stock pursuant to this prospectus from time to time through public or private transactions at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at privately negotiated prices. The Selling Stockholders may sell shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the Selling Stockholders, the purchasers of the shares, or both. For additional information on the methods of sale that may be used by the Selling Stockholders, see the section entitled "Plan of Distribution" on page 13. For a list of the Selling Stockholders, see the section entitled "Selling Stockholders" on page 9.

We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the Selling Stockholders of such shares. We are paying the cost of registering the shares of common stock covered by this prospectus as well as various related expenses. The Selling Stockholders are responsible for all selling commissions, transfer taxes and other costs related to the offer and sale of their shares.

You should carefully read this prospectus and any amendments or supplements accompanying this prospectus, together with any documents incorporated by reference herein or therein, before you make your investment decision.

The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their common shares hereunder following the effective date of the registration statement of which this prospectus forms a part.

------

Our common stock is listed on the NYSE American under the symbol "RMED." On January 30, 2023, the last reported sale price of our common stock was $3.16 per share.

**Investing in our securities involves a high degree of risk. See "[<u>Risk Factors</u>](#RISK_FACTORS)" on page 5 of this prospectus and in the documents incorporated by reference in this prospectus, as updated by any applicable prospectus supplement, and other future filings we make with the Securities and Exchange Commission that are incorporated by reference into this prospectus, for a discussion of the factors you should consider carefully before deciding to purchase our securities.** 

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.** 

The date of this prospectus is , 2023.

------

#### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
|  [<u>ABOUT THIS PROSPECTUS</u>](#ABOUT_THIS_PROSPECTUS_TC_ABOUT_THIS_PR) | 1 |
|  [<u>PROSPECTUS SUMMARY</u>](#PROSPECTUS_SUMMARY_TC_PROSPECTUS_SUMMA) | 2 |
|  [<u>RISK FACTORS</u>](#RISK_FACTORS) | 5 |
|  [<u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</u>](#SPECIAL_NOTE_REGARDING_FORWARDLOOKING_ST) | 6 |
|  [<u>USE OF PROCEEDS</u>](#USE_PROCEEDS) | 8 |
|  [<u>SELLING STOCKHOLDERS</u>](#SELLING_STOCKHOLDERS) | 9 |
|  [<u>PLAN OF DISTRIBUTION</u>](#PLAN_DISTRIBUTION) | 13 |
|  [<u>LEGAL MATTERS</u>](#LEGAL_MATTERS) | 14 |
|  [<u>EXPERTS</u>](#EXPERTS) | 14 |
|  [<u>WHERE YOU CAN FIND ADDITIONAL INFORMATION</u>](#WHERE_YOU_CAN_FIND_ADDITIONAL_INFORMATIO) | 15 |
|  [<u>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</u>](#INCORPORATION_CERTAIN_INFORMATION_BY_REF) | 15 |

---

------

#### ABOUT THIS PROSPECTUS
We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the heading "Where You Can Find Additional Information," before buying any of the securities being offered.

You should rely only on the information contained or incorporated by reference in this prospectus. We and the Selling Stockholders have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus may only be used where it is legal to offer and sell shares of our common stock. If it is against the law in any jurisdiction to make an offer to sell these shares, or to solicit an offer from someone to buy these shares, then this prospectus does not apply to any person in that jurisdiction, and no offer or solicitation is made by this prospectus to any such person. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. Our business, financial condition, results of operations and prospects may have changed since such date. Information contained on our website is not a part of this prospectus.

A prospectus supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplement together with additional information described below under the heading "Where You Can Find Additional Information."

This prospectus may contain references to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the® or™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

------

#### PROSPECTUS SUMMARY
*This summary highlights important features of this offering and the information contained elsewhere in or incorporated by reference into this prospectus. Because this is only a summary, it does not contain all of the information that you should consider before investing in our securities. You should carefully read this entire prospectus and any applicable prospectus supplement, including the information contained under the heading "Risk Factors" and all other information included or incorporated by reference into this prospectus and any applicable prospectus supplement in their entirety before you invest in our securities.* 

*Unless otherwise stated, all references in this prospectus to "we," "us," "our," the "Company" and similar designations refer to Ra Medical Systems, Inc.* 

#### Company Overview
Ra Medical Systems, Inc. (the "Company"), together with its wholly owned operating subsidiary Catheter Precision, LLC ("Catheter"), is an innovative medical device company bringing to market new solutions that improve the treatment of cardiac arrhythmias. As previously disclosed in the Merger 8-K, following its stock-for-stock merger transaction with Catheter Precision, Inc. (the "Merger"), the Company does not expect to continue its legacy lines of business or use its legacy assets, including the DABRA Excimer Laser System and the DABRA 2.0 catheter, we are no longer pursuing an atherectomy indication for use, and we do not intend to complete the atherectomy clinical study. We have instead shifted the entire focus of our operations to Catheter's product lines and the development of unique technology for electrophysiology procedures.

The Company's lead product, VIVO™ (an acronym for View Into Ventricular Onset), is an FDA-cleared and CE mark product that utilizes non-invasive inputs to locate the origin of ventricular arrhythmias. VIVO has been used in more than 800 procedures in leading U.S. and European hospitals under a limited commercial launch that commenced in the third quarter of 2021. Preparations are underway for a full commercial launch in the first quarter of 2023. The Company's product portfolio also includes the Amigo®, a robotic arm that serves as a catheter control device. The Company is developing a third product, anticipated to be released in 2023, which is a device to assist in the closure of the percutaneous insertion site used in minimally invasive procedures, such as catheter ablation.

The Company was formed on September 4, 2002 in the state of California and reincorporated in Delaware on July 14, 2018. The Merger closed on January 9, 2023. For further description of the Merger, the concurrent financing, and accompanying changes to our capitalization, board of directors, and management, please see the Merger 8-K, as amended.

Historical financial statements of Catheter Precision, Inc., as well as pro forma financial statements for the combined company are available in our previous SEC filings as follows:

• Catheter's Audited financial statements as of December 31, 2021 and 2020, and for the years then ended ([<u>Page F-44 et seq. of our Preliminary Proxy Statement (Amendment No. 1) filed November 4, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000119312522277180/d375656dprer14a.htm#tx375656_86));

• Catheter's Unaudited financial statements as of and for the nine months ended September 30, 2022 and September 30, 2021 ([<u>Exhibit 99.1 to our Form 8-K/A filed January 19, 2023</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000558/rmed-ex991_113.htm)); and

• Unaudited pro forma condensed combined financial information related to the Merger as of and for the nine months ended September 30, 2022 and for the year ended December 31, 2021 ([<u>Exhibit 99.2 to our Form 8-K/A filed January 19, 2023</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000558/rmed-ex992_70.htm)).

------

In addition, Catheter's Management's Discussion and Analysis ("Catheter MD&A") with respect to the foregoing historical financials are available in our previous SEC filings as follows:

• Catheter MD&A with respect to fiscal years ended December 31, 2020 and December 31, 2021 is available beginning at [<u>page 196 of our Preliminary Proxy Statement (Amendment No. 1) filed November 4, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000119312522277180/d375656dprer14a.htm#tx375656_71) ;

• Catheter MD&A with respect to the nine months ended September 30, 2022 and September 30, 2021 is available as [<u>Exhibit 99.3 to our Form 8-K/A filed January 19, 2023</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000558/rmed-ex993_26.htm) .

#### Company Information
Our principal executive offices are located at 1670 Highway 160 West, Suite 205, Fort Mill, SC 29708, and our telephone number is 973-691-2000. Our corporate website address is www.ramed.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and is not considered part of, this filing. You should not rely on any such information in making your decision whether to purchase our common stock. We make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.

------

#### THE OFFERING
Common stock offered by Selling Stockholders Up to 331,608 shares of common stock, that are issuable upon the exercise of the Series E warrants that were privately issued pursuant to the Inducement Letter, upon closing of the Warrant Repricing.

Use of proceeds We will not receive any proceeds from the sale of shares of common stock by the Selling Stockholders.

Offering price The Selling Stockholders may sell all or a portion of their shares through public or private transactions at prevailing market prices or at privately negotiated prices. See "Plan of Distribution."

Risk factors You should read the "Risk Factors" section included in this prospectus, and the risk factors incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.

NYSE American symbol "RMED"

The Selling Stockholders may offer and sell up to 331,608 shares of our common stock. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the Selling Stockholders for offer and resale, we are referring to the shares of common stock that may be issued upon exercise of Series E Warrants issued in the Warrant Repricing. When we refer to the Selling Stockholders in this prospectus, we are referring to the Selling Stockholder identified in this prospectus and its permitted transferees or other successors-in-interest that may be identified, to the extent required, in a supplement to this prospectus or a post-effective amendment to the registration statement of which this prospectus is a part.

------

#### RISK FACTORS
Investing in our securities involves a high degree of risk. Before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part, you should carefully consider, in addition to the risks and uncertainties discussed under "Special Note Regarding Forward-Looking Statements" below, the risk factors set forth under "Risk Factors" in our previous SEC filings, all of which are incorporated by reference into this prospectus:

• our most recent Annual Report on Form 10-K, as amended,

• our most recent Quarterly Reports on Form 10-Q filed subsequent to such filing,

• discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC, and

• risks with respect to Catheter's business contained in our revised Preliminary Proxy Statement (Amendment No. 1) filed with the SEC on November 4, 2022.

The Risk Factors set forth in the filings described above may be amended, supplemented or superseded from time to time by other reports and/or prospectus supplements we file with the SEC in the future, and you should carefully consider any such additional or modified risk factors and other information provided in any such future filings that may be available after the date of this prospectus before making your investment decision.

If any of the risks set forth in the filings described above actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and/or the available secondary market for our securities may diminish or become non-existent, and you could lose all or part of your investment or lose liquidity in the shares. The risks and uncertainties we describe in the documents incorporated by reference herein are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial could materially adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment.

------

#### SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions, and projections about the business and future financial results of the medical device industry, and other legal, regulatory and economic developments. In some cases, you can identify forward-looking statements by terms such as "may," "will," "intend," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "project," "predict," "potential," "continue," "likely," and similar expressions (including their use in the negative) intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about competition from larger and more established companies in our markets, our ability to successfully grow our business and legislative, regulatory and economic developments, including changing business conditions in the industries in which we operate and the economy in general, as well as financial performance, expectations with respect to our business and product development, including VIVO and the vessel closure device; litigation outcomes; the listing status of our common stock; the anticipated closing of the Securities Purchase Agreement described below under "Selling Stockholders – Relationships with Selling Stockholders" and amount of financing to be received in connection therewith, and existing and/or prospective customers.

In addition, our forward-looking statements are based on current plans, estimates and projections, and therefore, you are cautioned not to place undue reliance on them. These statements may discuss goals, intentions, plans and/or expectations as to future plans, trends, events, results of operations or financial condition, listed status of our common stock or other matters, all of which are based on current beliefs of our management, as well as assumptions made by, and information currently available to, management.

Forward-looking statements contained in this prospectus and in our other SEC filings speak only as of the date on which the statements were made and are not guarantees of future performance. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results

------

could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future, and we have no intention to do so.

No forward-looking statement can be guaranteed, and our actual results could differ materially from those projected or discussed in our forward-looking statements for many reasons, including the risks and uncertainties described above and those discussed in our SEC filings and incorporated herein by reference as described under "Risk Factors." Given these risks and uncertainties, readers should not place undue reliance on our forward-looking statements and should carefully consider such risks and uncertainties, as well as additional risks and uncertainties that may be described in other documents filed by us from time to time with the SEC, including any prospectus supplements we may file after the date of this prospectus. See "*Where You Can Find Additional Information*" beginning on page 15 of this prospectus.

------

#### USE OF PROCEEDS
We are filing the registration statement of which this prospectus is a part to permit holders of the shares of our common stock described in the section entitled "Selling Stockholders" to resell such shares. We are not selling any securities under this prospectus and we will not receive any proceeds from the sale or other disposition of shares of our common stock held by the Selling Stockholders. The Selling Stockholders will receive all of the proceeds from this offering.

The Selling Stockholders will pay any discounts, commissions, fees of underwriters, selling brokers or dealer managers and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees, printing fees, NYSE American listing fees and fees and expenses of our counsel and our accountants, including our independent registered public accounting firms.

------

#### SELLING STOCKHOLDERS
This prospectus covers the resale or other disposition of up to 331,608 shares of our common stock by the Selling Stockholders named below, and their donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer (collectively, the "Selling Stockholders"). Since January 9, 2023, the closing date of the Warrant Repricing, we have issued to the Selling Stockholders Series E Warrants to purchase a total of 331,608 shares of our common stock. See "Prospectus Summary—Warrant Repricing."

The table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of our common stock by the Selling Stockholders as of January 30, 2023. The information in the table below with respect to the Selling Stockholders has been obtained from the respective Selling Stockholders. The Selling Stockholders may sell all, some or none of the shares of common stock subject to this prospectus. See "Plan of Distribution" as it may be supplemented and amended from time to time. We do not know how long the Selling Stockholders will hold the shares before selling them, or if they will ever exercise any of their Series E Warrants to acquire shares.

Except as set forth below under "Relationship with Selling Stockholders," we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the shares.

The table below includes, for each Selling Stockholder: (i) all shares of our common stock beneficially held by such selling stockholder as of January 30, 2023, (ii) the number of shares of our common stock that may be offered under this prospectus, and (iii) the number of shares and percentage of our common stock beneficially owned by the Selling Stockholders assuming all of the shares of our common stock registered hereunder are sold. The table below and footnotes assume that the Selling Stockholders will sell all of the shares listed. However, because the Selling Stockholders may sell all or some of their shares under this prospectus from time to time, or in another permitted manner, we cannot provide assurances as to the actual number of shares that will be sold by the Selling Stockholders, or that will be held by the Selling Stockholders after completion of any sales.

The percentages of shares owned after the offering are based on 2,824,504 shares of common stock outstanding as of January 30, 2023, which includes the shares of common stock offered by this prospectus and assumes that all Series E Warrants have been exercised.

The number of shares of common stock into which the Warrants are convertible is limited to that number of shares of common stock which would result in the stockholder, together with its affiliates, having an aggregate beneficial ownership of no more than 4.99% or 9.99% of the total issued and outstanding shares of common stock, as elected by each warrant holder (the "4.99% Blocker" or the "9.99% Blocker", as applicable). The numbers shown in the table do not reflect operation of the 4.99% Blocker or the 9.99% Blocker.

The Warrants are also subject to an additional blocker (the "Exchange Blocker") designed to prohibit issuance of shares in amounts that would exceed stock exchange limitations prior to receipt of stockholder approval. Under the Exchange Blocker, the Series E Warrants may not be exercised in amounts that would result in the issuance of Common Stock equaling 20% or more of our outstanding Common Stock, after aggregation with the shares of Common Stock issued to the Master Fund in connection with the repricing as described below under Relationships with Selling Stockholders, prior to receipt of stockholder approval for such issuance. The Company plans to seek stockholder approval in the first quarter of 2023. The offering amount shown in the table below assumes that the Company will obtain such stockholder approval.

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to our common stock. Generally, a person "beneficially owns" shares of our common stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to acquire voting or disposition rights within 60 days.

------

Information about the Selling Stockholders may change over time. Any changed information will be set forth in an amendment to the registration statement or supplement to this prospectus, to the extent required by law.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Shares of Common<br>Stock Beneficially<br>Owned Prior to<br>Offering** | **Shares of Common<br>Stock Beneficially<br>Owned Prior to<br>Offering** | **Number of<br>Shares of<br>Common Stock<br>Being Offered (1)** | **Shares of Common<br>Stock to be<br>Beneficially Owned<br>After Offering (2)** | **Shares of Common<br>Stock to be<br>Beneficially Owned<br>After Offering (2)** |
| **Name of Selling Stockholder** | **Number** | **Percentage** | **Offered** | **Number** | **Percentage** |
|  Armistice Capital Master Fund Ltd. <sup>(</sup><sup>3</sup><sup>)</sup> | 100433(4) |  | 331608(5) | 0  | 0% |

---

(1) The number of shares of our common stock in the column "Number of Shares of Common Stock Being Offered" represents all of the shares of our common stock that a Selling Stockholder may offer and sell from time to time under this prospectus. 231,175 of these shares are not currently beneficially owned due to the requirement that stockholder approval must be obtained before the Series E Warrants can be exercised to acquire them.

(2) We do not know when or in what amounts a Selling Stockholder may offer shares for sale. The Selling Stockholders might not sell any or might sell all of the shares offered by this prospectus. Because the Selling Stockholders may offer all or some of the shares pursuant to this offering, and because, except as set forth elsewhere in this prospectus, there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the Selling Stockholders after completion of the offering. However, for purposes of this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the Selling Stockholders. For each Selling Stockholder , we have assumed exercise in full of the Series E Warrants held by all Selling Stockholders, notwithstanding the 4.99% Blocker and 9.99% Blocker described above.

(3) The shares of Common Stock are directly held by Armistice Capital Master Fund Ltd. (the "Master Fund"), a Cayman Islands exempted company, and may be deemed to be indirectly beneficially owned by (i) Armistice Capital, LLC ("Armistice"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest s therein. The Series E Warrants are subject to the 4.99% Blocker described above. Due to the Exchange Blocker, Series E Warrants to acquire 231,175 of the shares will only become exercisable if and when stockholder approval is obtained. The address of the Master Fund is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.

(4) Represents the number of shares of Common Stock underlying Series E Warrants that may be issued prior to stockholder approval. As described above, shareholder approval is required to lift the Exchange Blocker and allow the issuance of 20% or more of our outstanding Common Stock, after aggregation with the shares of Common Stock issued to the Master Fund in connection with the repricing as described below under "Relationships with Selling Stockholders."

(5) Consists of the 331,608 shares of Common Stock underlying Series E Common Stock Warrants . The disclosures of amounts and percentages of Common Stock beneficially owned prior to the offering and to be beneficially owned after the offering do not include any of the shares of Common Stock or warrants to purchase Common Stock that may issued upon the closing of the PIPE described below under "Relationships with Selling Stockholders."

#### Relationship s with Selling Stockholders
As discussed in greater detail in the Merger 8-K, on January 9, 2023, we entered into the following agreements with the Master Fund:

• the Inducement Letter with the Master Fund, pursuant to which we repriced existing warrants in connection with their exercise, following which we issued shares of Common Stock, as well as the Series E Warrants referenced above, to the Master Fund; and

• a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Master Fund.

Pursuant to the Securities Purchase Agreement, the Master Fund agreed to purchase, for an aggregate purchase price of up to approximately $8.0 million (such transaction, the "Private Placement"):

------

(a) Class A Units at a price that is the lower of $3.00 per unit and 90% of the 5 day volume weighted average closing price of the Company Common Stock immediately prior to obtainment of the approval of the Company's stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants (as each is defined below), with each Class A Unit to consist of one share of Common Stock, one Series F Common Stock Purchase Warrant ("Series F Warrant"), and one Series G Common Stock Purchase Warrant ("Series G Warrant" and together with the Series F Warrants, the "PIPE Warrants"); and

(b) Class B Units at a price of $1,000.00 per unit, with each Class B Unit to consist of one share of a new series of the Company's preferred stock, designated as Series A Convertible Preferred Stock, par value $0.0001 (the "PIPE Preferred Stock"), and one Series F Warrant and one Series G Warrant for each share of Company Common Stock underlying the PIPE Preferred Stock. Each share of PIPE Preferred Stock will be convertible into a number of shares of Ra Medical common stock equal to $1,000 divided by the lower of $3.00 and 90% of the 5 day volume weighted average closing price of the Company common stock immediately prior to obtainment of the approval of the Company's stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants (the "Preferred Conversion Price")).

The allocation between Class A and Class B units will be determined by Master Fund prior to their issuance. The closing under the Securities Purchase Agreement and the sale and issuance of the Class A Units and Class B Units (and the issuance of any underlying Common Stock) is subject to the approval of the Company's stockholders.

The Company has an obligation to use commercially reasonable efforts to call and hold a meeting of the Company's stockholders to approve the exercise of the PIPE Warrants and conversion of the PIPE Preferred Stock not later than the 75<sup>th</sup> day from the date of the Securities Purchase Agreement; however, the Company may cancel the Private Placement at any time prior to obtaining stockholder approval.

The PIPE Warrants will be exercisable at an exercise price of $3.00 per share, subject to adjustments as provided under the terms of the PIPE Warrants. The PIPE Warrants will be exercisable at any time on or after the closing date of the Private Placement until the expiration thereof, except that the PIPE Warrants cannot be exercised if, after giving effect thereto, the holder thereof would (together with the holder's affiliates and any other persons acting as a group together with the holder or any of its affiliates) beneficially own more than 4.99% (the "Maximum Percentage") of the outstanding shares of common stock of the Company, which Maximum Percentage may be increased or decreased by the holder thereof with written notice to the Company to any other percentage specified not in excess of 9.99%. The Series F Warrants have a term of two years from the date stockholder approval is obtained, and the Series G Warrants have a term of six years from the date that stockholder approval is obtained.

Shares of PIPE Preferred Stock are non-convertible until the Company obtains stockholder approval. After stockholder approval is obtained, subject to certain ownership limitations as described below, shares of PIPE Preferred Stock are convertible at any time at the option of the holder into shares of Company Common Stock at the Preferred Conversion Price. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.

Subject to limited exceptions, holders of shares of PIPE Preferred Stock will not have the right to convert any portion of their Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or up to 9.99% at the election of the holder) of the number of shares of the Company's common stock outstanding immediately after giving effect to its conversion.

Holders of PIPE Preferred Stock, if issued, will be entitled to receive dividends on shares of PIPE Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the Common Stock. Except as otherwise required by law, the PIPE Preferred Stock does not have voting rights. However, as long as any shares of PIPE Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the PIPE Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the PIPE Preferred Stock, (b) alter or amend the Certificate of Designation for the PIPE Preferred Stock, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of PIPE Preferred Stock, (d) increase the number of authorized shares of PIPE Preferred Stock, or (e) enter into any agreement with respect to any of the

------

foregoing. The PIPE Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. The holders of PIPE Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Company Stock would receive if the PIPE Preferred Stock were fully converted (disregarding for such purposes any conversion limitations) to Company Common Stock, which amounts will be paid pari passu with all holders of Company Common Stock.

The Company also entered into a registration rights agreement (the "Registration Rights Agreement") with the Master Fund in connection with the Securities Purchase Agreement, under which the Company is required to register the resale of the shares of Common Stock, the shares issuable upon exercise of the Warrants, and the shares issuable upon the conversion of the PIPE Preferred Stock.

The securities to be issued to the Master Fund under the Securities Purchase Agreement will be issued pursuant to an exemption from registration pursuant to Section 4(a)(2) of the Securities Act. The sale of the securities pursuant to the Securities Purchase Agreement has not been registered under the Securities Act or any state securities laws. The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This description is not an offer to sell or the solicitation of an offer to buy the securities to be issued pursuant to the Securities Purchase Agreement.

Further information is provided in the Merger 8-K and the exhibits thereto.

------

#### PLAN OF DISTRIBUTION
Each Selling Stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market for the common stock or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:

• ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

• block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

• purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

• an exchange distribution in accordance with the rules of the applicable exchange;

• privately negotiated transactions;

• settlement of short sales;

• in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;

• through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

• a combination of any such methods of sale; or

• any other method permitted pursuant to applicable law.

The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling

------

Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

#### LEGAL MATTERS
Arnall Golden Gregory LLP will pass upon the validity of the shares of common stock being offered hereby.

#### EXPERTS
The financial statements incorporated by reference in this prospectus by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and to the Company's Preliminary Proxy Statement dated November 3, 2022 (Amendment No. 1), have been audited by Haskell & White LLP, the Company's independent registered public accounting firm, as set forth in their report thereon, and incorporated herein by reference. The report of Haskell & White LLP includes an explanatory paragraph that expresses substantial doubt regarding the Company's ability to continue as a going concern. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

The financial statements as of December 31, 2020, and for the year then ended, incorporated by reference in this prospectus, have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

The financial statements of Catheter Precision, Inc. as of December 31, 2021 and 2020, and for the years then ended, have been audited by WithumSmith+Brown, PC, Catheter's independent registered public accounting firm, and incorporated herein by reference in reliance upon their report, which includes an explanatory paragraph regarding the substantial doubt concerning Catheter's ability to continue as a going concern. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of said firm as an expert in auditing and accounting.

------

#### WHERE YOU CAN FIND ADDITIONAL INFORMATION
We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at *http://www.sec.gov*.

We make available, free of charge, through our investor relations website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, statements of changes in beneficial ownership of securities and amendments to those reports and statements as soon as reasonably practicable after they are filed with the SEC. The address for our website is *www.ramed.com*. The contents on our website are not part of this prospectus, and the reference to our website does not constitute incorporation by reference into this prospectus of the information contained at that site.

This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our securities. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC's website.

#### INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to "incorporate by reference" into this prospectus the information we file with the SEC. This means that we can disclose important information to you by referring you to those documents. Any statement contained in a document incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein, or in any subsequently filed document, which also is incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

We hereby incorporate by reference into this prospectus the following documents that we have filed with the SEC under the Exchange Act (other than current reports on Form 8-K, or portions thereof, furnished under Items 2.02 or 7.01 of Form 8-K):

• [<u>our Annual Report on Form 10-K (excluding Item 15) for the year ended December 31, 2021, filed with the SEC on March 24, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022011555/rmed-10k_20211231.htm) ;

• [<u>our Annual Report on Form 10-K/A for the year ended December 31, 2021, filed with the SEC on July 13, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022025660/rmed-10ka_20211231.htm) ;

• [<u>the information specifically incorporated by reference in our Annual Report on Form 10-K for the year ended December 31, 2021, from our Definitive Proxy Statement related to our 2022 Annual Meeting of Stockholders, filed with the SEC on April 21, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022014994/rmed-def14a_20220603.htm) ;

• our Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2022, filed with the SEC on [<u>May 16, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022020432/rmed-10q_20220331.htm) ; for the quarterly period ended June 30, 2022, filed with the SEC on [<u>August 15, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716621/000156459022029521/rmed-10q_20220630.htm) ; and for the quarterly period ended September 30, 2022, filed with the SEC on [<u>November 14, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022037665/rmed-10q_20220930.htm) ;

• our Current Reports on Form 8-K and amendments thereto filed with the SEC on [<u>January 24, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716621/000156459022002008/rmed-8k_20220118.htm) , [<u>February 9, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716621/000156459022004272/rmed-8k_20220204.htm) , [<u>April 20, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716621/000156459022014909/rmed-8k_20220415.htm) , [<u>May 16, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716621/000156459022020412/rmed-8k_20220510.htm) (excluding information furnished thereunder), [<u>June 6, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022022586/rmed-8k_20220603.htm) , [<u>July 8, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022025521/rmed-8k_20220708.htm) (excluding information furnished thereunder), [<u>July 18, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022025910/rmed-8k_20220714.htm) , [<u>July 22, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022026217/rmed-8k_20220722.htm) , as amended on [<u>September 2, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022030981/rmed-8ka_20220722.htm) , [<u>August 12, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022029307/rmed-8k_20220810.htm) , [<u>August 17, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022029707/rmed-8k_20220816.htm) , [<u>September 2, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022030972/rmed-8k_20220831.htm) , [<u>September 12, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022031424/rmed-8k_20220909.htm) , [<u>September 20, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022032010/0001564590-22-032010-index.htm) , [<u>September 27, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022032327/0001564590-22-032327-index.htm) , [<u>September 29, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022032641/0001564590-22-032641-index.htm) , [<u>October 4, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022033267/0001564590-22-033267-index.htm) , [<u>October 17, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022034366/rmed-8k_20221017.htm) , [<u>October 20, 2022</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1716621/000156459022034765/rmed-8k_20221020.htm) , [<u>November 3, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022036622/0001564590-22-036622-index.htm) , [<u>November 29, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022038507/0001564590-22-038507-index.htm) , [<u>December 2, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022038854/0001564590-22-038854-index.htm) , [<u>December 15, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022039348/0001564590-22-039348-index.htm) , and [<u>January 13, 2023</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm) , as amended [<u>January 19, 2023</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000558/0001564590-23-000558-index.htm) ; and

• [<u>our Definitive Proxy Statement related to our September 20, 2022 Special Meeting of Stockholders, filed with the SEC on August 29, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022030319/rmed-def14a_20220920.htm) ;

• [<u>our revised Preliminary Proxy Statement filed with the SEC on November 4, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000119312522277180/d375656dprer14a.htm) ; and

------

• [<u>the description of our common stock contained in our Registration Statement on Form 8-A that we filed with the SEC on December 17, 2020, including any amendment or report filed for the purpose of updating such description</u>](http://www.sec.gov/Archives/edgar/data/1716621/000095012320012698/rmed-8a_20201217.htm) .

All documents that we file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than current reports on Form 8-K, or portions thereof, furnished under Items 2.02 or 7.01 of Form 8-K) (i) after the initial filing date of the registration statement of which this prospectus forms a part and prior to the effectiveness of such registration statement and (ii) after the date of this prospectus, and prior to the termination of the offering shall be deemed to be incorporated by reference in this prospectus from the date of filing of the documents, unless we specifically provide otherwise. Information that we file with the SEC will automatically update and may replace information previously filed with the SEC. To the extent that any information contained in any current report on Form 8-K or any exhibit thereto, was or is furnished to, rather than filed with the SEC, such information or exhibit is specifically not incorporated by reference.

Upon written or oral request made to us at the address or telephone number below, we will, at no cost to the requester, provide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all of the information that has been incorporated by reference in this prospectus (other than an exhibit to a filing, unless that exhibit is specifically incorporated by reference into that filing), but not delivered with this prospectus. You may also access this information on our website at www.ramed.com by viewing the "Financials & Filings" subsection of the "Investors" menu. No additional information on our website is deemed to be part of or incorporated by reference into this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

Ra Medical Systems, Inc.

1670 Highway 160 West, Suite 205

Fort Mill, SC 29708

973-691-2000

------

#### PART II

#### INFORMATION NOT REQUIRED IN PROSPECTUS

#### Item 14. Other Expenses of Issuance and Distribution
The following table sets forth the fees and expenses incurred or expected to be incurred by us in connection with the issuance and distribution of the securities being registered hereby, other than underwriting discounts and commissions.

---

| | |
|:---|:---|
|  SEC registration fee | $117 |
|  Legal fees and expenses | 30000 |
|  Accounting fees and expenses | 48000 |
|  Printing fees and engraving expenses |  |
|  Miscellaneous expenses | 6883 |
|  Total | $______<u>85,000</u> |

---

#### Item 15. Indemnification of Directors and Officers
Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that eliminate the personal liability of our directors and executive officers for monetary damages for breach of their fiduciary duties as directors or officers.

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation or is or was serving at the request of a corporation against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated certificate of incorporation and amended and restated bylaws will provide that:

We shall indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of us and, with respect to any criminal proceeding, had no reasonable cause to believe such person's conduct was unlawful.

We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.

We are required to advance expenses, as incurred, to its directors and officers in connection with defending a proceeding, except that such director or officer shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

We will not be obligated pursuant to the amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.

------

The rights conferred in the amended and restated certificate of incorporation and amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with its directors, officers, employees, and agents and to obtain insurance to indemnify such persons.

We may not retroactively amend the bylaw provisions to reduce our indemnification obligations to directors, officers, employees, and agents.

We have entered into indemnification agreements with our directors and executive officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law and also to provide for certain additional procedural protections, in addition to the indemnification provided for in our amended and restated certificate of incorporation and bylaws. We also intend to enter into indemnification agreements with any new directors and executive officers in the future.

We have purchased and currently intend to maintain insurance on behalf of each and any person who is or was a director or officer of us against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

See also the undertakings set out in response to Item 17 herein.

#### Item 16. Exhibits
The following exhibits are filed as part of this registration statement.

------

#### EXHIBIT INDEX

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit** |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Number** | **Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| 2.1\* | [<u>Amended and Restated Agreement and Plan of Merger, dated January 9, 2023, by and among Ra Medical Systems, Inc., Rapid Merger Sub 1, Inc., Rapid Merger Sub 2, LLC, and Catheter Precision, Inc.</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/rmed-ex21_25.htm) | 8-K | 001-38677 | 2.1 | 01/13/2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1.1 | [<u>Amended and Restated Certificate of Incorporation of the Registrant.</u>](http://www.sec.gov/Archives/edgar/data/1716621/000119312518289731/d617129dex31.htm) | 8-K | 001-38677 | 3.1 | 10/1/2018 |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1.2 | [<u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Ra Medical Systems, Inc., dated as of September 20, 2022</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022032010/rmed-ex31_33.htm) | 8-K | 001-38677 | 3.1 | 09/20/2022 |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1.3 | [<u>Certificate of Designation of Series X Convertible Preferred Stock</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/rmed-ex31_24.htm) | 8-K | 001-38677 | 3.1 | 01/13/2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1.4 | [<u>Certificate of Designation of Series A Convertible Preferred Stock</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/rmed-ex32_37.htm) | 8-K | 001-38677 | 3.2 | 01/13/2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;3.2.1 | [<u>Amended and Restated Bylaws of the Registrant.</u>](http://www.sec.gov/Archives/edgar/data/1716621/000119312518289731/d617129dex32.htm) | 8-K | 001-38677 | 3.2 | 10/1/2018 |
| &nbsp;&nbsp;&nbsp;&nbsp;3.2.2 | [<u>Bylaws Amendment (incorporated by reference to Exhibit 3.1 of the Company's Form 8-K filed on August 17, 2022)</u>](http://www.sec.gov/Archives/edgar/data/1716621/000156459022029707/rmed-ex31_7.htm) | 8-K | 001-38677 | 3.1 | 08/17/2022 |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\*\* | [<u>Opinion of Arnall Golden Gregory LLP.</u>](rmed-ex51_45.htm) |  |  |  |  |
| 23.1\*\* | [<u>Consent of Haskell & White LLP, Independent Registered Public Accounting Firm.</u>](rmed-ex231_9.htm) |  |  |  |  |
| 23.2\*\* | [<u>Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.</u>](rmed-ex232_8.htm) |  |  |  |  |
| 23.3\*\* | [<u>Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm.</u>](rmed-ex233_7.htm) |  |  |  |  |
| 23.4\*\* | [<u>Consent of Arnall Golden Gregory LLP (Included in Exhibit 5.1).</u>](rmed-ex51_45.htm) |  |  |  |  |
| 24.1\*\* | [<u>Power of Attorney (included on the signature page to this Registration Statement).</u>](#POWER_OF_ATTORNEY) |  |  |  |  |
| 107\*\* | [<u>Filing Fee Table.</u>](rmed-exfilingfees_6.htm) |  |  |  |  |

---

^ Previously Filed.

\*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.

\*\* Filed herewith.

------

#### Item 17. Undertakings
(a)The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; and

(4) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(5) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on January 31, 2023.

---

| | |
|:---|:---|
|  | RA MEDICAL SYSTEMS, INC. |
|  By: | /s/ Jonathan Will McGuire |
|  | Jonathan Will McGuire |
|  | Chief Executive Officer |

---

#### Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jonathan Will McGuire and David Jenkins, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agent, with full power of each to act alone, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments and any related registration statements filed pursuant to Rule 462 and otherwise), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their substitute or resubstitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
|  **Signature** | **Title** | **Date** |
|  /s/ Jonathan Will McGuire | Director and Chief Executive Officer | January 31, 2023 |
|  Jonathan Will McGuire | (Principal Executive Officer) |  |
|  /s/ Brian Conn | Interim Chief Financial Officer | January 31, 2023 |
|  Brian Conn | (Principal Financial and Accounting Officer) |  |
|  /s/ David A. Jenkins | Executive Chairman of<br> the Board of Directors | January 31, 2023 |
|  David A. Jenkins |  |  |
|  /s/ James J. Caruso | Director | January 31, 2023 |
|  James J. Caruso |  |  |
|  /s/ Martin Colombatto | Director | January 31, 2023 |
|  Martin Colombatto |  |  |
|  /s/ Susanne Meline | Director | January 31, 2023 |
|  Susanne Meline |  |  |

---

## Exhibit 5.1

#### Exhibit 5.1
January 31, 2023

Ra Medical Systems, Inc.

1670 Highway 160 West, Suite 205

Fort Mill, SC 29708

---

| | |
|:---|:---|
| **Re:** | **Registration Statement on Form S-3** |

---

Ladies and Gentlemen:

At your request, we have examined the Registration Statement on Form S-3 (the "Registration Statement"), filed by Ra Medical Systems, Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission (the "Commission") in connection with the registration pursuant to the Securities Act of 1933, as amended (the "Act"), of the Securities (as defined below).

The Registration Statement relates to the proposed offer and resale or distribution from time to time by the Selling Stockholder named in the prospectus contained in the Registration Statement and any supplement thereto or their transferees (the "Selling Stockholders"), pursuant to Rule 415 under the Act, as set forth in the Registration Statement, the prospectus contained therein (the "Prospectus") and the supplements to the prospectus referred to therein (each a "Prospectus Supplement"), of up to an aggregate of 331,608 shares of the Company's common stock, $0.0001 par value per share (the "Securities"), issuable upon exercise of the Company's Series E Common Stock Purchase Warrants (the "Warrants"), as described in the Registration Statement.

The Securities are to be sold from time to time as set forth in the Registration Statement, the Prospectus contained therein and the Prospectus Supplements.

We have examined instruments, documents, certificates and records that we have deemed relevant and necessary for the basis of our opinions hereinafter expressed. In such examination, we have assumed: (a) the authenticity of original documents and the genuineness of all signatures; (b) the conformity to the originals of all documents submitted to us as copies; (c) the truth, accuracy and completeness of the information, representations and warranties contained in the instruments, documents, certificates and records we have reviewed; (d) that the Registration Statement, and any amendments thereto (including post-effective amendments), will have become effective under the Act; (e) that a Prospectus Supplement, to the extent necessary, will have been filed with the Commission describing the Securities offered thereby; (f) that the Securities will be issued and sold in compliance with applicable U.S. federal and state securities laws and in the manner stated in the Registration Statement and any applicable Prospectus Supplement, and in the manner and on the terms and conditions set forth in and required by the Warrants; (g) the legal capacity of all natural persons; (h) after the issuance of any Securities offered pursuant to the Registration Statement, the total number of issued shares of the Company's common stock ("Common Stock"), together with the total number of shares of Common Stock issuable upon the exercise, exchange, conversion or settlement, as the case may be, of any exercisable, exchangeable or convertible security (including without limitation any Preferred Stock, Warrant or Unit) then outstanding, will not exceed the total number of authorized shares of Common Stock available for issuance under the Company's certificate of incorporation as then in effect; and (i) at the time of the issuance of the Securities, the Company will be validly existing as a corporation and in good standing under the laws of the State of Delaware. We have also assumed the authority of persons signing any documents on behalf of parties thereto other than the Company and the

------

due authorization, execution and delivery of all documents by the parties thereto other than the Company. We have not independently established or verified any facts relevant to the opinions expressed herein, but have relied upon statements and representations of the officers and other representatives of the Company and Covered Guarantors. As to any facts material to the opinions expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company.

Based on the examinations and assumptions set forth above, we are of the opinion that, when issued by the Company against payment therefor in accordance with the terms of the Warrants, the Securities will be duly authorized, validly issued, fully paid and nonassessable. It is understood that this opinion is to be used only in connection with the offer and resale of the Securities while the Registration Statement is in effect. We assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof. We express no opinion as to the laws of any other jurisdiction, other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.

\* \* \*

------

We hereby consent to the filing of this opinion as an exhibit to the above-referenced Registration Statement and to the use of our name wherever it appears in the Registration Statement, the Prospectus, any Prospectus Supplement, and in any amendment or supplement thereto. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

We do not find it necessary for the purposes of this opinion, and accordingly we do not purport to cover herein, the application of the securities or "Blue Sky" laws of the various states to the issuance and sale of the Securities.

Very truly yours,

/s/ Arnall Golden Gregory LLP

ARNALL GOLDEN GREGORY LLP

## Exhibit 23.1

#### Exhibit 23.1

#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the prospectus that constitutes a part of this Registration Statement on Form S-3 of Ra Medical Systems, Inc. (the "Company") of our report dated March 23, 2022, relating to our audit of the Company's financial statements as of December 31, 2021, and for the year then ended, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as amended, which report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern, and our report dated March 23, 2022, except for Note 19, as to which the date is November 3, 2022, relating to our audit of the Company's financial statements as of December 31, 2021, and for the year then ended, included in the Company's Preliminary Proxy Statement (Amendment No. 1) dated November 3, 2022, which report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern.

We also consent to the reference to us under the heading "Experts."

*/s/ Haskell & White LLP*

HASKELL & WHITE LLP

Irvine, California

January 27, 2023

## Exhibit 23.2

#### Exhibit 23.2
![](gwkstbehxnvn000001.jpg)

#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report

dated March 16, 2021 (January 14, 2022 as to the effects of the discontinued operations as described in

Note 3 and November 3, 2022 as to the effects of the reverse stock split as described in Note 19) relating to the financial statements of Ra Medical Systems, Inc., appearing in the Annual Report on Form 10-K/A (Amendment No. 1) of Ra Medical Systems, Inc. for the year ended December 31, 2021. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

*/s/Deloitte & Touche LLP*

San Diego, California

January 31, 2023

## Exhibit 23.3

#### Exhibit 23.3

#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

#### We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-3 of our report dated April 22, 2022, which includes an explanatory paragraph relating to Catheter Precision, Inc.'s ability to continue as a going concern, relating to the financial statements of Catheter Precision, Inc., as of and for the years ended December 31, 2021, and 2020, which financial statements were included both as Exhibit 99.4 to Ra Medical Systems, Inc.'s Form 8-K dated September 12, 2022, and in Ra Medical Systems, Inc.'s revised Preliminary Proxy Statement (Amendment No. 1) dated November 3, 2022, both of which are incorporated by reference to this Form S-3, and to the reference to our Firm under the caption "Experts" in the Prospectus.
*/s/ WithumSmith+Brown, PC* 

WithumSmith+Brown, PC

East Brunswick, New Jersey

January 31, 2023

## Ex-Filing

#### Exhibit 107

#### Calculation of Filing Fee Table

#### Form S-3
(Form Type)

#### Ra Medical Systems, Inc.
(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Security Type | Security Class Title | Fee Calculation Rule | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Equity | Common Stock, $0.0001 par value per share | 457(c)<br>331608 <sup>(1)</sup><br>$3.21 <sup>(2</sup><sup>)</sup> | $1064461.68 <sup>(2)</sup> | .0001102 | $117.30 |
|  | Total Offering Amounts | Total Offering Amounts | $1064.461 | .0001102 | $117.30 |
|  | Total Fee Offsets | Total Fee Offsets |  |  | ---- |
|  | Net Fee Due | Net Fee Due |  |  | $117.30 |

---

(1) The amount registered consists of up to 331,608 shares of common stock, par value $0.0001 per share, issuable upon exercise of warrants to purchase common stock. Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers such an indeterminate amount of shares of common stock as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.

(2) Estimated in accordance with Rule 457(c) solely for the purpose of calculating the total registration fee on the basis of $3.21 per share, which represents the average of the high and low prices of the Registrant's common stock as reported on the NYSE American on January 27, 2023.